Latest Articles

  • In Reply: Diabetes therapy and cardiac risk (November 2014)
    Robert S. Zimmerman, MD and Kevin M. Pantalone, DO
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 140-141; DOI: https://doi.org/10.3949/ccjm.82c.03002

    A reader comments on diabetes therapy and cardiac risk (November 2013).

  • Left atrial appendage closure: An emerging option in atrial fibrillation when oral anticoagulants are not tolerated
    Left atrial appendage closure: An emerging option in atrial fibrillation when oral anticoagulants are not tolerated
    David C. Peritz, MD and Eugene H. Chung, MD, FACC, FHRS, FAHA
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 167-176; DOI: https://doi.org/10.3949/ccjm.82a.14117

    Can patients undergo a percutaneous procedure to reduce their risk of stroke and avoid lifelong anticoagulation treatment?

  • When the dissociation curve shifts to the left
    Bhuvnesh Aggarwal, MD, Ruhail Kohli, MD, Rendell Ashton, MD and Moises Auron, MD
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 156-160; DOI: https://doi.org/10.3949/ccjm.82a.14044

    The patient’s clinical signs and oxygen saturation monitor indicated hypoxemia, but her blood gases were normal.

  • Is triglyceride therapy worth the effort?
    Michael Miller, MD, FACC, FAHA
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 162-166; DOI: https://doi.org/10.3949/ccjm.82a.13157

    Levels do matter, but no trials of triglyceride-lowering have been done. Weight loss and exercise are encouraged.

  • Does this patient need ultrasonography of the leg to evaluate for deep vein thrombosis?
    C. Jessica Dine, MD, MSHPR and Sara L. Wallach, MD
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 153-155; DOI: https://doi.org/10.3949/ccjm/82a.14071

    If the pretest probability of deep vein thrombosis is low, a normal D-dimer level is enough to rule it out.

  • But how many people died? Health outcomes in perspective
    Vinay Prasad, MD
    Cleveland Clinic Journal of Medicine March 2015, 82 (3) 146-150; DOI: https://doi.org/10.3949/ccjm.82a.14058

    Before dispensing advice, we should know the effect of what we recommend on all meaningful outcomes.

  • Denosumab: A novel antiresorptive drug for osteoporosis
    Ernest Suresh, MD, FRCP and Bo Abrahamsen, MD, PhD
    Cleveland Clinic Journal of Medicine February 2015, 82 (2) 105-114; DOI: https://doi.org/10.3949/ccjm.82a.13173

    What denosumab is, how it works, how well it works, and practical prescribing tips.

  • Syncope from a twiddled ICD
    Fatima Adhi, MD, Gurshawn Singh, MD, Wayne Tsuang, MD and Eduardo Mireles-Cabodevila, MD
    Cleveland Clinic Journal of Medicine February 2015, 82 (2) 81-82; DOI: https://doi.org/10.3949/ccjm.82a.14095

    A patient playing (“twiddling”) with his or her implanted cardioverter-defibrillator can dislodge the lead.

  • The ‘skinny’ on eosinophilic esophagitis
    David A. Katzka, MD
    Cleveland Clinic Journal of Medicine February 2015, 82 (2) 83-88; DOI: https://doi.org/10.3949/ccjm.82gr.14008

    Often starting in childhood, this disease progresses until the esophagus is visibly narrowed on radiography.

  • Should patients stop taking aspirin for primary prevention?
    Jeremiah P. Depta, MD, MPHS and Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
    Cleveland Clinic Journal of Medicine February 2015, 82 (2) 91-96; DOI: https://doi.org/10.3949/ccjm.82a.14114

    In view of the evidence, routine use of aspirin for primary prevention is not recommended, even in patients with diabetes.

Pages